Skip to contentH
Heron Therapeutics, Inc.
H
HRTXHeron Therapeutics, Inc. Q2 2022 · 10-Q
Revenue$27.63M$27.63M+23.1% vs Q2 2021 Net Income-$56.36M-$56.36MN/M vs Q2 2021 EPS Diluted-$0.55-$0.55N/M vs Q2 2021 Operating Income-$49,498,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Heron Therapeutics, Inc. · CIK 818033 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$28,695,000N/M Margins · derivedOperating margin-179.1%+90.3 pt vs Q2 2021
Net margin-204.0%+67.9 pt vs Q2 2021
ended Jun 30, 2022 · filed Aug 9, 2022 · 40 d after period end